- Previous Close
4,286.08 - Open
0.00 - Bid --
- Ask --
- Day's Range
4,286.08 - 4,286.08 - 52 Week Range
4,150.00 - 5,911.37 - Volume
0 - Avg. Volume
3,326 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
94.59 - EPS (TTM)
45.31 - Earnings Date Feb 19, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
www.iconplc.com42,250
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: ICLRN.MX
View MorePerformance Overview: ICLRN.MX
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICLRN.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICLRN.MX
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
9.00%
Return on Assets (ttm)
4.17%
Return on Equity (ttm)
7.99%
Revenue (ttm)
8.31B
Net Income Avi to Common (ttm)
747.89M
Diluted EPS (ttm)
45.31
Balance Sheet and Cash Flow
Total Cash (mrq)
695.51M
Total Debt/Equity (mrq)
37.00%
Levered Free Cash Flow (ttm)
1.07B